case_images: PMC5968288_01
case_images: Overview of diagnostic and therapeutic measures and outcomes over time. CT, computed tomography; MRI, magnetic resonance imaging; PD, progressive disease; PR, partial remission; RTx, radiotherapy; SD, stable disease.
case_images: cro-0011-0246-g01.jpg
case_images: PMC5968288_01_cro-0011-0246-g01.jpg
case_images: F1
case_images: Figure 1 shows an overview of all diagnostic and therapeutic measures taken and their outcome over time. Abdominal staging CT assessments were conducted every 4 months until progressive disease, diagnosed on 2 August 2017 (Fig. 1, 2b, c).
case_images: Abdominal CT images during trabectedin treatment. a Disease progression after pazopanib treatment. b Second diagnosis of partial remission after 6.5 months of trabectedin treatment (first partial remission observed after 3 months of trabectedin). c Disease progression after 22 months of trabectedin treatment. CT, computed tomography; PD, progressive disease; PR, partial remission.
case_images: cro-0011-0246-g02.jpg
case_images: PMC5968288_01_cro-0011-0246-g02.jpg
case_images: F2
case_images: Pazopanib was subsequently stopped due to disease progression (Fig. 2a). Abdominal staging CT assessments were conducted every 4 months until progressive disease, diagnosed on 2 August 2017 (Fig. 1, 2b, c).